MBX Biosciences, Inc. (MBX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $30.60: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 12.12; Below-average business quality.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone... Read more
Sell if holding. Engine safety override at $30.60: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 12.12; Below-average business quality. Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — MBX Biosciences, Inc.
Latest news
- Earnings Scheduled For May 14, 2026 — benzinga May 14, 2026 neutral
- Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70 — benzinga May 12, 2026 positive
- Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86 — benzinga May 12, 2026 positive
- Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $70 — benzinga May 11, 2026 positive
- MBX Biosciences Announces Multiple Updates On Obesity Portfolio; Preliminary Blinded Phase 1 Data For MBX 4291 Show Phar — benzinga May 11, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 10.7% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $30.60: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 12.12; Below-average business quality. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $28.26. Score 5.2/10, moderate confidence.
Take-profit target: $60.11 (+97.8% upside). Prior stop was $28.26. Stop-loss: $28.26.
Quality below floor (1.6 < 4.0).
MBX Biosciences, Inc. trades at a P/E of N/A (forward -7.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover MBX with a consensus score of 4.1/5. Average price target: $69.
What does MBX Biosciences, Inc. do?MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of...
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.